SARS-CoV-2 Pseudovirus, Delta (B.1.617.2) variant

Comprehensive Neutralization Assay Solutions for Advancing COVID-19 Research

Get your pseudovirus

B.1.617.2 (Delta) variant Advantages

This pseudovirus is pseudotyped with the Spike Glycoprotein of SARS-CoV-2 virus, Delta (B.1.617.2) variant (Genbank : QUD52764.1). This pseudovirus carries a modified genome that expresses a luciferase reporter gene. The reporter gene can be replaced with GFP if requested.

Up to 1,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 1 µL per well

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293 ACE2⁺ cells.

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Lead Time: 2 - 3 week

We provide you with freshly produced pseudoviruses

QC report Order Now

Features

Enable specific detection

Expression of Spike glycoprotein as the sole surface antigen

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions

Characterization of thermal stability

Stable at least 6 month at -80 °C

Support high-throughput screening

QC reports Order Now

Applications

Pseudoviruses provide a safe and versatile platform for SARS-CoV-2 virus research and the development of therapeutic countermeasures. SARS-CoV-2 pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting specific strains of the SARS-CoV-2 virus.

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

QR reports Order Now

B.1.617.2 (Delta) Variant's Background

The SARS-CoV-2 Delta variant (lineage B.1.617.2) is a highly transmissible (CDC) variant of concern that was first identified in India in late 2020 and rapidly spread worldwide. Delta carries several key mutations in the spike protein—including L452R, T478K, and P681R—which enhance viral entry into host cells and contribute to increased replication efficiency. Compared with earlier SARS-CoV-2 strains, the Delta variant is associated with higher viral loads and faster transmission, allowing it to outcompete previously circulating variants and become the globally dominant lineage by mid-2021 (CDC). The Delta variant showed partial resistance to neutralizing antibodies (Planas et al. 2021), highlighting the importance of continuous surveillance and updated vaccine strategies.

SARS-CoV-2 pseudovirus, B.1.617.2 (Delta) in Publications

The emergence and global spread of the SARS-CoV-2 B.1.617.2 (Delta) variant, characterized by increased transmissibility and partial immune escape, underscored the need for effective vaccines and antiviral strategies against evolving viral strains. By eliminating the need to handle infectious BSL-3 virus, pseudovirus neutralization assays offer a safe, rapid, scalable, and standardized platform for evaluating neutralizing monoclonal antibodies (mAbs) and antiviral compounds targeting the spike (S) protein of SARS-CoV-2 variants.

• Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variants

Order Now

Documentation

Quality control reports

Access QR reports

SDS

Access SDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL